BeiGene Files 2023 Annual Report Amendment
Ticker: BEIGF · Form: 10-K/A · Filed: Jan 8, 2025 · CIK: 1651308
| Field | Detail |
|---|---|
| Company | Beigene, LTD. (BEIGF) |
| Form Type | 10-K/A |
| Filed Date | Jan 8, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, financials, debt
TL;DR
BeiGene amended its 2023 10-K, updating financials including loans from China Merchants Bank.
AI Summary
BeiGene, Ltd. filed an amendment (10-K/A) to its 2023 annual report on January 8, 2025. The filing provides updated financial information for the fiscal year ending December 31, 2023. Key financial data includes total assets, total liabilities, and equity, with specific figures for loans payable to China Merchants Bank.
Why It Matters
This amendment provides updated financial disclosures for BeiGene, Ltd., which is crucial for investors and stakeholders to assess the company's financial health and performance as of December 31, 2023.
Risk Assessment
Risk Level: low — This filing is an amendment to a routine annual report, primarily providing updated financial data rather than disclosing new significant risks.
Key Numbers
- 2023-12-31 — Fiscal Year End (The period for which financial information is reported.)
- 2025-01-08 — Filing Date (The date the 10-K/A was filed with the SEC.)
Key Players & Entities
- BeiGene, Ltd. (company) — Filer of the 10-K/A
- China Merchants Bank (company) — Lender for loans payable
- January 8, 2025 (date) — Filing date of the amendment
- December 31, 2023 (date) — Fiscal year end for the reported period
FAQ
What specific financial information was updated in this 10-K/A filing?
The filing provides updated financial data for the fiscal year ending December 31, 2023, including details on loans payable to China Merchants Bank.
What is the accession number for this filing?
The accession number for this filing is 0001651308-25-000005.
What is the standard industrial classification for BeiGene, Ltd.?
The standard industrial classification for BeiGene, Ltd. is Pharmaceutical Preparations [2834].
When was the original 10-K filed for the fiscal year ending December 31, 2023?
While this is an amendment filed on January 8, 2025, the original 10-K for the fiscal year ending December 31, 2023, would have been filed earlier, typically around February 2024.
What type of loan is mentioned in relation to China Merchants Bank?
The filing mentions 'ShortTermBankLoanDueDecember252024Member' in relation to loans payable to China Merchants Bank.
Filing Stats: 3,010 words · 12 min read · ~10 pages · Grade level 13 · Accepted 2025-01-08 06:02:32
Key Financial Figures
- $0.0001 — resenting 13 Ordinary Shares, par value $0.0001 per share ONC The NASDAQ Global Select
Filing Documents
- bgne-20231231.htm (10-K/A) — 246KB
- exhibit231-2023q410ka.htm (EX-23.1) — 8KB
- exhibit232-2023q410ka.htm (EX-23.2) — 8KB
- exhibit311-2023q41.htm (EX-31.1) — 10KB
- exhibit312-2023q41.htm (EX-31.2) — 10KB
- exhibit321-2023q41.htm (EX-32.1) — 6KB
- bgne-20231231_g1.jpg (GRAPHIC) — 16KB
- 0001651308-25-000005.txt ( ) — 1337KB
- bgne-20231231.xsd (EX-101.SCH) — 10KB
- bgne-20231231_cal.xml (EX-101.CAL) — 28KB
- bgne-20231231_def.xml (EX-101.DEF) — 67KB
- bgne-20231231_lab.xml (EX-101.LAB) — 141KB
- bgne-20231231_pre.xml (EX-101.PRE) — 92KB
- bgne-20231231_htm.xml (XML) — 59KB
Exhibits and Financial Statement Schedules
Item 15. Exhibits and Financial Statement Schedules The following documents are filed as part of this Amendment: (a) (2) Financial Information of Parent Company - Financial Statements Schedule I for the years ended December 31, 2023, 2022, and 2021. (3) The exhibits filed as part of this Amendment are set forth on the Exhibit Index immediately following the financial schedule. The Exhibit Index is incorporated herein by reference. Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of BeiGene, Ltd. We have audited the consolidated financial statements of BeiGene, Ltd. (the Company) as of December 31, 2023 and 2022, and for each of the two years in the period ended December 31, 2023, and have issued our report thereon dated February 26, 2024 included elsewhere in the Form 10-K. Our audits of the consolidated financial statements included the financial statement schedule listed in Item 15 of this Form 10-K/A (the "schedule") as of December 31, 2023 and 2022, and for each of the two years in the period ended December 31, 2023. This schedule is the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's schedule, based on our audits. In our opinion, the schedule presents fairly, in all material respects, the information set forth therein when considered in conjunction with the consolidated financial statements. /s/ Ernst & Young LLP Boston, Massachusetts January 8, 2025 Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of BeiGene, Ltd. We have audited the consolidated statements of operations, comprehensive loss, cash flows and shareholders' equity of BeiGene, Ltd. (the Company) for the year ended December 31, 2021, and the related notes (collectively referred to as the "consolidated financial statements") and have issued our report thereon dated February 28, 2022, except for the effects on the consol
SIGNATURES
SIGNATURES Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment to be signed on its behalf by the undersigned, thereunto duly authorized. BEIGENE, LTD. Date: January 8, 2025 By: /s/ JOHN V. OYLER John V. Oyler Chief Executive Officer and Chairman (Principal Executive Officer)